Arcturus Therapeutics Holdings Inc. (ARCT) stock
ARCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3010% below fair value
$7.97−0.34 (-4.09%)
Close on Nov 17, 2026Market cap $226.53MP/E –Yield –
Arcturus Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Arcturus Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$102.30M. For fiscal 2025 it was -$76.26M. The highest annual figure on record is $12.18M in fiscal 2022.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$76.26M | – |
| FY2024 | Dec 31, 2024 | -$95.67M | – |
| FY2023 | Dec 31, 2023 | -$78.21M | -742.2% |
| FY2022 | Dec 31, 2022 | $12.18M | – |
| FY2021 | Dec 31, 2021 | -$202.85M | – |
| FY2020 | Dec 31, 2020 | -$71.52M | – |
| FY2019 | Dec 31, 2019 | -$25.51M | – |
| FY2018 | Dec 31, 2018 | -$21.81M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$25.55M | – |
| Q1 FY2026 | Mar 31, 2026 | -$28.93M | – |
| Q4 FY2025 | Dec 31, 2025 | -$31.31M | – |
| Q3 FY2025 | Sep 30, 2025 | -$16.51M | – |
| Q2 FY2025 | Jun 30, 2025 | -$11.62M | – |
| Q1 FY2025 | Mar 31, 2025 | -$16.83M | – |
| Q4 FY2024 | Dec 31, 2024 | -$33.39M | – |
| Q3 FY2024 | Sep 30, 2024 | -$10.74M | – |
| Q2 FY2024 | Jun 30, 2024 | -$21.13M | – |
| Q1 FY2024 | Mar 31, 2024 | -$30.41M | -306.1% |
| Q4 FY2023 | Dec 31, 2023 | -$18.27M | -115.0% |
| Q3 FY2023 | Sep 30, 2023 | -$19.31M | – |
| Q2 FY2023 | Jun 30, 2023 | -$55.37M | – |
| Q1 FY2023 | Mar 31, 2023 | $14.76M | – |
| Q4 FY2022 | Dec 31, 2022 | $121.45M | – |
| Q3 FY2022 | Sep 30, 2022 | -$36.81M | – |
| Q2 FY2022 | Jun 30, 2022 | -$22.09M | – |
| Q1 FY2022 | Mar 31, 2022 | -$50.38M | – |
| Q4 FY2021 | Dec 31, 2021 | -$37.65M | – |
| Q3 FY2021 | Sep 30, 2021 | -$53.82M | – |
| Q2 FY2021 | Jun 30, 2021 | -$53.72M | – |
| Q1 FY2021 | Mar 31, 2021 | -$57.67M | – |
| Q4 FY2020 | Dec 31, 2020 | -$31.08M | – |
| Q3 FY2020 | Sep 30, 2020 | -$20.94M | – |
| Q2 FY2020 | Jun 30, 2020 | -$10.04M | – |
| Q1 FY2020 | Mar 31, 2020 | -$9.46M | – |
| Q4 FY2019 | Dec 31, 2019 | -$10.82M | – |
| Q3 FY2019 | Sep 30, 2019 | -$7.62M | – |
| Q2 FY2019 | Jun 30, 2019 | -$572.00K | – |
| Q1 FY2019 | Mar 31, 2019 | -$6.51M | – |
| Q4 FY2018 | Dec 31, 2018 | -$711.00K | – |
| Q3 FY2018 | Sep 30, 2018 | -$4.36M | – |
| Q2 FY2018 | Jun 30, 2018 | -$10.07M | – |
See a number that looks wrong?